Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
Panelists discuss how isatuximab- and daratumumab-based quadruplet regimens compare in patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM), with a particular focus on minimal residual disease (MRD) negativity data from the IMROZ and CEPHEUS trials, presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition.
EP: 1.Expert Insights: Evolving Treatment Landscape in NDMM
EP: 2.Key Highlights From the PERSEUS and CASSIOPEIA Studies
EP: 3.ASH 2024 Updates —AURIGA: Daratumumab Plus Lenalidomide in Maintenance Post Transplant
EP: 4.Anti-CD38 Quadruplet Induction Regimens in TE NDMM: New Standard of Care
EP: 5.Clinical Perspectives: Selecting Between Daratumumab- and Isatuximab-Containing Quadruplet Induction Regimens
EP: 6.ASH 2024 Highlights: GMMG-HD7 Study
EP: 7.Where Are We Going? Future Perspectives on Navigating the Treatment Paradigm in Transplant-Eligible NDMM
EP: 8.Key Highlights: CEPHEUS Trial SubQ Dara-VRd vs VRd in Transplant-Eligible or Transplant-Deferred NDMM
EP: 9.Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
EP: 10.Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
EP: 11.Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
EP: 12.Future Perspectives: What’s Next in NDMM?
EP: 13.Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM
Video content above is prompted by the following:
- How do isatuximab-based regimens compare with daratumumab-based quadruplet regimens in patients with transplant-ineligible/deferred NDMM?
- Please comment on the latest results and approval from the IMROZ study evaluating Isa-VRd vs VRd in transplant-ineligible/deferred NDMM.
- What is the significance of MRD negativity as a primary outcome in studies presented at ASH 2024?
- CEPHEUS, MRD Negativity
- IMROZ, MRD Negativity
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
